الفهرس | Only 14 pages are availabe for public view |
Abstract Tuberculosis treatment strategy includes standard short course of drugs delivery, lasting 6 months for newly diagnosed patients and 8 months for relapsed patients. DM may passively influence the achievement of WHO ambitious target for TB management including reduction in TB incidence by 25% and mortality rate by 75% respectively in 2025 and affecting on the pharmacokinetic of anti-TB agents. Therefore, a systematic review and meta-analysis study was conducted for revealing the effect of diabetes mellitus on pharmacokinetics of anti-tuberculosis drugs (isoniazid and rifampicin). Moreover, an experimental study was performed for evaluating of pharmacodynamic effects of anti-tuberculosis drugs (isoniazid and rifampicin) in diabetic rats. |